Biogen (BIIB) Stock: Charts & Financials

Biogen Inc. (BIIB)BIIBBiogen Inc.

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Total Current Assets	9.19B	9.19B	8.97B	8.94B	7.97B	7.63B	7.46B	6.83B	7.11B
Cash & Cash Equivalents	3.38B	3.38B	3.01B	3.86B	2.76B	2.60B	2.38B	1.70B	1.91B
Short-Term Investments	900.00M	900.00M	807.20M	97.60M	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	4.28B	4.28B	3.82B	3.96B	2.76B	2.60B	2.38B	1.70B	1.91B
Accounts Receivable	1.79B	1.79B	1.87B	1.85B	2.08B	2.00B	1.87B	1.99B	2.08B
Inventory	1.95B	1.95B	2.17B	2.21B	2.27B	2.27B	2.46B	2.47B	2.51B
Total Assets	29.48B	29.48B	29.44B	29.21B	28.33B	28.03B	28.05B	28.31B	26.80B
Property, Plant & Equipment	3.27B	3.27B	3.32B	3.41B	3.43B	3.48B	3.54B	3.59B	3.64B
Goodwill	6.49B	6.49B	6.49B	6.49B	6.49B	6.48B	6.48B	6.49B	6.23B
Intangible Assets	9.05B	9.05B	9.18B	9.33B	9.47B	9.58B	9.69B	9.81B	8.23B
Long-Term Investments	465.60M	465.60M	750.60M	167.10M	224.00M	186.00M	226.70M	353.30M	354.10M
Total Current Liabilities	3.00B	3.00B	3.35B	3.29B	3.18B	5.30B	5.53B	5.42B	3.11B
Accounts Payable	358.50M	358.50M	432.00M	413.10M	408.40M	391.50M	424.20M	422.70M	354.50M
Short-Term Debt	0.00	0.00	80.40M	0.00	0.00	1.75B	1.75B	1.75B	0.00
Total Liabilities	10.83B	10.83B	11.18B	11.00B	10.70B	11.05B	11.33B	11.95B	10.91B
Long-Term Debt	6.29B	6.29B	6.58B	6.29B	6.28B	4.55B	4.55B	4.55B	6.29B
Total Debt	6.56B	6.56B	6.95B	6.59B	6.59B	6.62B	6.63B	6.65B	6.66B
Net Debt (Cash)	3.18B	3.18B	3.94B	2.73B	3.84B	4.02B	4.26B	4.95B	4.75B
Total Shareholders' Equity	18.65B	18.65B	18.26B	18.21B	17.63B	16.98B	16.72B	16.36B	15.89B
Common Stock	100K	100K	100K	100K	100K	100K	100K	100K	100K
Retained Earnings	20.87B	20.87B	20.55B	20.60B	20.14B	19.50B	19.26B	18.99B	18.60B
Current Ratio	3.06	3.06	2.68	2.72	2.50	1.44	1.35	1.26	2.29
Debt to Equity Ratio	0.35	0.35	0.38	0.36	0.37	0.39	0.40	0.41	0.42

Quarterly Report

TTM

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Quarter ended Jun 2024

Total Current Assets

9.19B

8.97B

8.94B

7.97B

7.63B

7.46B

6.83B

7.11B

Cash & Cash Equivalents

3.38B

3.01B

3.86B

2.76B

2.60B

2.38B

1.70B

1.91B

Short-Term Investments

900.00M

807.20M

97.60M

0.00

Cash & Short-Term Investments

4.28B

3.82B

3.96B

2.76B

2.60B

2.38B

1.70B

1.91B

Accounts Receivable

1.79B

1.87B

1.85B

2.08B

2.00B

1.87B

1.99B

2.08B

Inventory

1.95B

2.17B

2.21B

2.27B

2.46B

2.47B

2.51B

Total Assets

29.48B

29.44B

29.21B

28.33B

28.03B

28.05B

28.31B

26.80B

Property, Plant & Equipment

3.27B

3.32B

3.41B

3.43B

3.48B

3.54B

3.59B

3.64B

Goodwill

6.49B

6.48B

6.49B

6.23B

Intangible Assets

9.05B

9.18B

9.33B

9.47B

9.58B

9.69B

9.81B

8.23B

Long-Term Investments

465.60M

750.60M

167.10M

224.00M

186.00M

226.70M

353.30M

354.10M

Total Current Liabilities

3.00B

3.35B

3.29B

3.18B

5.30B

5.53B

5.42B

3.11B

Accounts Payable

358.50M

432.00M

413.10M

408.40M

391.50M

424.20M

422.70M

354.50M

Short-Term Debt

0.00

80.40M

0.00

1.75B

0.00

Total Liabilities

10.83B

11.18B

11.00B

10.70B

11.05B

11.33B

11.95B

10.91B

Long-Term Debt

6.29B

6.58B

6.29B

6.28B

4.55B

6.29B

Total Debt

6.56B

6.95B

6.59B

6.62B

6.63B

6.65B

6.66B

Net Debt (Cash)

3.18B

3.94B

2.73B

3.84B

4.02B

4.26B

4.95B

4.75B

Total Shareholders' Equity

18.65B

18.26B

18.21B

17.63B

16.98B

16.72B

16.36B

15.89B

Common Stock

100K

Retained Earnings

20.87B

20.55B

20.60B

20.14B

19.50B

19.26B

18.99B

18.60B

Current Ratio

3.06

2.68

2.72

2.50

1.44

1.35

1.26

2.29

Debt to Equity Ratio

0.35

0.38

0.36

0.37

0.39

0.40

0.41

0.42

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Current Assets	8.97B	7.46B	6.86B	9.79B	7.86B	6.89B	8.38B	7.64B
Cash & Cash Equivalents	3.01B	2.38B	1.05B	3.42B	2.26B	1.33B	2.91B	1.22B
Short-Term Investments	807.20M	0.00	0.00	1.47B	1.54B	1.28B	1.56B	2.31B
Cash & Short-Term Investments	3.82B	2.38B	1.05B	4.89B	3.80B	2.61B	4.48B	3.54B
Accounts Receivable	1.87B	1.87B	2.10B	2.14B	1.96B	2.33B	2.47B	2.49B
Inventory	2.17B	2.46B	2.53B	1.34B	1.35B	1.07B	804.20M	929.90M
Total Assets	29.44B	28.05B	26.84B	24.55B	23.88B	24.62B	27.23B	25.29B
Property, Plant & Equipment	3.32B	3.54B	3.73B	3.70B	3.79B	3.84B	3.67B	3.60B
Goodwill	6.49B	6.48B	6.22B	5.75B	5.76B	5.76B	5.76B	5.71B
Intangible Assets	9.18B	9.69B	8.36B	1.85B	2.22B	3.08B	3.53B	3.12B
Long-Term Investments	750.60M	226.70M	460.70M	705.70M	892.00M	772.10M	1.41B	1.38B
Total Current Liabilities	3.35B	5.53B	3.43B	3.27B	4.30B	3.74B	4.86B	3.30B
Accounts Payable	432.00M	424.20M	403.30M	491.50M	589.20M	454.90M	530.80M	370.50M
Short-Term Debt	80.40M	1.75B	150.00M	0.00	999.10M	0.00	1.50B	0.00
Total Liabilities	11.18B	11.33B	12.05B	11.17B	12.92B	13.93B	13.90B	12.26B
Long-Term Debt	6.58B	4.55B	6.79B	6.28B	6.27B	7.43B	4.46B	5.94B
Total Debt	6.95B	6.63B	7.34B	6.61B	7.60B	7.83B	6.37B	5.94B
Net Debt (Cash)	3.94B	4.26B	6.29B	3.19B	5.34B	6.50B	3.45B	4.71B
Total Shareholders' Equity	18.26B	16.72B	14.80B	13.40B	10.90B	10.70B	13.34B	13.04B
Common Stock	100K	100K	100K	100K	100K	100K	100K	100K
Retained Earnings	20.55B	19.26B	17.63B	16.47B	13.91B	13.98B	16.46B	16.26B
Current Ratio	2.68	1.35	2.00	2.99	1.83	1.84	1.72	2.32
Debt to Equity Ratio	0.38	0.40	0.50	0.49	0.70	0.73	0.48	0.46

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Total Current Assets

8.97B

7.46B

6.86B

9.79B

7.86B

6.89B

8.38B

7.64B

Cash & Cash Equivalents

3.01B

2.38B

1.05B

3.42B

2.26B

1.33B

2.91B

1.22B

Short-Term Investments

807.20M

0.00

1.47B

1.54B

1.28B

1.56B

2.31B

Cash & Short-Term Investments

3.82B

2.38B

1.05B

4.89B

3.80B

2.61B

4.48B

3.54B

Accounts Receivable

1.87B

2.10B

2.14B

1.96B

2.33B

2.47B

2.49B

Inventory

2.17B

2.46B

2.53B

1.34B

1.35B

1.07B

804.20M

929.90M

Total Assets

29.44B

28.05B

26.84B

24.55B

23.88B

24.62B

27.23B

25.29B

Property, Plant & Equipment

3.32B

3.54B

3.73B

3.70B

3.79B

3.84B

3.67B

3.60B

Goodwill

6.49B

6.48B

6.22B

5.75B

5.76B

5.71B

Intangible Assets

9.18B

9.69B

8.36B

1.85B

2.22B

3.08B

3.53B

3.12B

Long-Term Investments

750.60M

226.70M

460.70M

705.70M

892.00M

772.10M

1.41B

1.38B

Total Current Liabilities

3.35B

5.53B

3.43B

3.27B

4.30B

3.74B

4.86B

3.30B

Accounts Payable

432.00M

424.20M

403.30M

491.50M

589.20M

454.90M

530.80M

370.50M

Short-Term Debt

80.40M

1.75B

150.00M

0.00

999.10M

0.00

1.50B

0.00

Total Liabilities

11.18B

11.33B

12.05B

11.17B

12.92B

13.93B

13.90B

12.26B

Long-Term Debt

6.58B

4.55B

6.79B

6.28B

6.27B

7.43B

4.46B

5.94B

Total Debt

6.95B

6.63B

7.34B

6.61B

7.60B

7.83B

6.37B

5.94B

Net Debt (Cash)

3.94B

4.26B

6.29B

3.19B

5.34B

6.50B

3.45B

4.71B

Total Shareholders' Equity

18.26B

16.72B

14.80B

13.40B

10.90B

10.70B

13.34B

13.04B

Common Stock

100K

Retained Earnings

20.55B

19.26B

17.63B

16.47B

13.91B

13.98B

16.46B

16.26B

Current Ratio

2.68

1.35

2.00

2.99

1.83

1.84

1.72

2.32

Debt to Equity Ratio

0.38

0.40

0.50

0.49

0.70

0.73

0.48

0.46

Balance Sheet

Quarterly Balance Sheet (USD)

Annual Balance Sheet (USD)